ArticleJournal of thoracic disease2021

Acceptability and feasibility of S-1 plus cisplatin adjuvant chemotherapy for completely resected non-small cell lung cancer: an open-label, single arm, multicenter, phase 2 trial.

Shugo Uematsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.